PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX

Preferred Label : PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX;

LOINC status : ACTIVE;

LOINC long common name : PhenX - human papillomavirus vaccine use protocol 100802;

LOINC short name : PhenX - HPV vaccine use protocol;

LOINC description : The interviewer asks the individual whether s/he ever received a human papillomavirus (HPV) vaccination. If the response is yes, the interviewer asks about number of shots received. If the participant answers yes to question 1, the interviewer should complete the rest of the protocol. If the participant answers no, then the protocol is deemed complete. The PhenX Working Group notes that GARDASIL is also known internationally as Silgard. European Medicines Agency. (2009, September 25). Silgard European Public Assessment Report. Waknine, Y. (2006, October 2). International approvals: Singulair and Gardasil/Silgard. Medscape Today. Note: GARDASIL by Merck & Co. is approved by the U.S. Food and Drug Administration (FDA) for use in females ages 9-26 and males ages 9-26. Note: CERVARIX is manufactured by GlaxoSmithKline Biologicals and approved by the FDA for use in females ages 10-25.;

Détails

Origin ID

94327-4;

UMLS CUI

C5241052;

Has component
- PhenX - human papillomavirus vaccine use protocol 100802 [LOINC component]
Has method
- PhenX [LOINC method]
Has system
- Patient [LOINC System]
- ^Patient [LOINC System]
Has time aspect
- Point in time (spot) [LOINC time aspect]
Panel of LOINC codes
- Have you ever had the HPV vaccination:Find:Pt:^Patient:Ord: [LOINC code]
- Number of human papillomavirus vaccine doses received:Num:Pt:^Patient:Qn: [LOINC code]
Semantic type(s)
- Clinical Attribute [UMLS semantic type]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients